MedTrace Logo

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

NCT04678440 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-07-02

Study results available
· View outcomes & findings →

Summary

In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo \[18F\]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

DRUG

[18F]F-AraG Imaging

Total body PET imaging using \[18F\]F-AraG

Sponsors & Collaborators

  • CellSight Technologies, Inc.

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Simon R Cherry, PhD · UC Davis

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2023-02-07
Completion
2023-02-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678440 on ClinicalTrials.gov